Luteinizing hormone releasing hormone, estrogen, and progesterone receptors in canine mammary lesions and tumor cell lines.
Nineteen canine mammary lesions were analyzed for estrogen receptor (ER), progesterone receptor (PR) and luteinizing hormone releasing hormone receptor (LHRHR) content. In addition, nine previously established canine mammary tumor cell lines with known ER and PR were analyzed for LHRHR. The incidence of receptors in the mammary tumor lesions was 21% for LHRHR, 10% for ER and 30% for PR. Statistical correlation was not observed between receptor status and diagnosis of malignant, benign, or hyperplastic lesions. A relationship between LHRHR and ER and PR content of canine mammary lesions or cell lines was not evident. The presence of functional hormone receptors offers opportunity for hormonal treatment of mammary cancer which may not be completely treatable by surgery. The observation of LHRHR in canine mammary tumors may offer therapeutic interventions other than surgery for mammary tumors unresponsive to antiestrogens.
Sartin
E A
EA
Department of Pathobiology, College of Veterinary Medicine, Auburn University, AL 36849-5519, USA.
Rahe
C H
CH
Wright
J C
JC
Sartin
J L
JL
D000818:Animals; D004285:Dogs; D005260:Female; D008321:Mammary Glands, Animal / Q000737:chemistry* / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000737:chemistry* / Q000473:pathology; D011960:Receptors, Estrogen / Q000032:analysis*; D011966:Receptors, LHRH / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D011960:Receptors, Estrogen; D011966:Receptors, LHRH; D011980:Receptors, Progesterone; D013629:Tamoxifen